The role of the pharmaceutical industry in diabetes, or any other research, is a mixed one. In the pharmaceutical industry research is allied to development, often within a unified research and development group. If separately administered, the functions are interdependent and often overlap. For illustrative purposes these functions will be described under three headings: [1] pharmaceutical development [2] applied research and [3] innovative research, acknowledging that the groupings might be debatable. The following draws heavily on British data for illustrative purposes because of inability to obtain comparable information for other European countries. While the numbers may differ in different countries, it is believed that the overall picture is similar throughout Europe.
Pharmaceutical Development
Close to and supporting pharmaceutical production, i. e. the actual manufacture of an active drug and its formulation into tablets, solutions, suspensions, etc., is technical research which involves pharmaceutical expertise and is clearly developmental in nature. Within research and development, it is one of the least glamorous roles, but is, nevertheless, essential to introduction of new products or extension of existing product lines. However, it implies in-house manufacture from raw materials and, consequently, concerns only about half of the 180 or so 'manufacturers' listed in the British National Formulary 1982 [4] . It also ensures that a consistent medicinal product meeting rigorous standards can be manufactured day in and day out. Following Banting and Best's demonstration of the properties of crude pancreatic extract in dogs, it helped to make insulin available for widespread clinical use within two years. Later followed the development of preparations of various 'long acting' and more recently 'highly purified' insulin for clinical use. Mundane technical problems need to be overcome, such as identifying protaminase activity in bulk crystalline insulin, which could ruin an 800 litre production batch of isophane insulin, equivalent to 80,000 x 10 ml vials 80 U insulin. This problem disappears with highly purified bulk insulin but others of a physico-chemical nature (e. g. unit 100 development), take its place. With 'human' insulin a reality, from whatever source, development for widespread clinical use will predictably present problems to be surmounted. The use of multiple dose insulin vials demands addition of preservatives to ensure sterility throughout the time of use by the patient, and studies continue as to the choice of the optimum effective and compatible agent. Technical expertise will be involved in preparing pharmaceutical products suitable for use in new insulin delivery systems, to obviate the risk of degradation and contamination of sterile material by later manipulation. Over many years, many man hours have been expended on the selection of suitable vehicles for delivery of insulin per nares, per os and per rectum with varying degrees of success, but no practical solution has yet appeared.
Applied Research
Applied research is a more sophisticated role undertaken by, perhaps, one-quarter of the companies listed in the British National Formulary [4] . It overlaps the technical research field and extends to, if not into, innovative research. It presupposes a starting point, for example a biologically active molecule, a known mechanism, and progresses from there. During such research new ideas, new approaches or new mechanisms may be identified which could be considered innovative. Contributions in this role are many and varied.
Fetal rabbit islet cells, protected by artificial membranes, have survived for long periods when implanted intraperitoneally into diabetic rats. Continuing function of the surviving implant has led to more normal metabolism in the recipient [7] . The phylogenetic age of the insulin molecule has been confirmed by demonstrating its presence in the brain of the blowfly [6] . When insulin was later demonstrated to be present in the earthworm, in~u-0012-186X/82/0023/0216/$01.00 lin farming seemed a possibility. Today, of course, the possibility of production of insulin in culture media is a real one, following the success of genetic manipulation of E. coli to produce human insulin as a feasible commercial proposition. Simultaneous chemical manipulation of the porcine insulin molecule has led to an identical end molecule. More relevant to the majority of diabetic subjects is the development of progressive generations of oral hypoglycaemic agents, stemming from the early sulphonamides which showed hypoglycaemic activity, and leading through carbutamide to the present molecules. While it is generally agreed that these have a predominantly endogenous insulin stimulating activity, there is evidence that some have extra-pancreatic effects, elucidation of which may contribute to the better understanding of diabetes.
Falling within this role and not to be lightly dismissed are sporadic claims, from different parts of the world, that various herbal concoctions have 'cured grandmother's diabetes'. While each should be evaluated thoroughly, in reality the industry cannot afford to study every such claim.
Whatever the problem, this work demands the highest standard of objective science since dubious results will waste time and money.
Innovative Research
Basic innovative research is the third role involving perhaps one-tenth of the listed companies in the British National Formulary, with an even smaller fraction involved in research in diabetes. The companies involved tend to be the larger ones with international interests looking for 'ethical products', but also dependent on 'over-the-counter' products for everyday income.
Companies tend to develop particular expertise in particular areas, for example, mood modifiers, purine/ pyrimidine metabolism, steroids, antibacterials, etc., so that the clinical observer with a brilliant idea may have to search around for appropriate takers.
Interdependence
However, it is the clinical observers whose contributions are often fundamental in this area. The management and observation of patients is in their hands and their insight and investigation can lead to new lines of research. Industrial involvement requires cross-fertilisation of ideas and of personnel, and this is happening more often. Frequently, therefore, the origin and initiation of innovative research may be obscured between academia and industry. Without close clinical collaboration the basic research scientist may develop an active agent and then have to identify the disease it will treat. The stories of both the introduction of insulin and the development of sulphonylureas illustrate this collaboration and interchange very well. 
Whence Sulphonylureas ?
The story of the sulphonylureas started from a different industrial background. During the nineteenth century development of 'aromatic' chemistry, Unverborden (1829) and Runge (1837) both prepared substances that Hofmann (1843) confirmed as identical and identified as aniline, as cited by Pledge [12] . This led to the rapid growth of the dye industry and German chemistry, in particular. By 1910, Ehrlich (cited in 11), having replaced empiricism in therapy by methodical investigation of certain classes of compounds, had established the antiseptic action of various acridine dyes. 11] . Coincident with the resulting rapid development of sulphonamide chemistry, Loubati6res [10] was observing the effects of prolonged insulin hypoglycaemia in animals, observations which later he brilliantly exploited. In 1942, Janbon [cited in 10] used a sulphonamide 2254 RP, synthesised in 1941 and supplied by the Soci6t6 Rh6ne-Poulenc, to treat about 30 cases of typhoid, of whom three died. Loubati6res, as a consequence of his hypoglycaemic studies, deduced that these deaths were due to profound and prolonged hypoglycaemia produced by the sulphonamide [10] . By 1944, he had made fundamental studies establishing the mode of action, and had undertaken limited studies in man, reported in his doctoral thesis of 1946 [cited in 10]. The human studies were interrupted and were not resumed until 1954-1955, which coincided with early reports on carbutamide, a Boehringer Mannheim compound. By 1956, tolbutamide had been synthesised by Hoechst [cited in 10].
Continued Interdependence
The need for collaboration between clinician and basic researcher continues today. For the various subpopulations of diabetic patients, the identification of specific treatments will probably stem mainly from clinical study and classification. It is very clear that diabetic patients can be crudely divided into Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) and the former appear to have occupied much of the discussion so far. The majority of diabetic patients are of the latter group, a mixed population in terms of aetiology and pathophysiology. In the continuing debate as to the significance of genetic disposition, infection, immune response, insulin resistance, receptor anomalies, enzyme disorders and other factors yet to be defined, clinical definition, aided by appropriate investigational techniques, will be fundamental. HLA antigens and other immunological 'markers' may help to categorise patients in relation to specific disorders.
With so many postulated factors, it is likely that all have a part to play, some larger than others, together with those yet to be identified. This raises the possibility that basic research in fields other than diabetes may give leads. Both industry and academia are actively interested in various polypeptides, prostaglandins, a-and t-blockers, to name but a few of the newer areas of understanding which have important implications in diabetes.
Obesity is said to be the most common complicating factor in degenerative diseases of Western man. It certainly complicates Type 2 diabetes with aggravation of hyperglycaemia. A safe remedy, whether based on central appetite control or increased peripheral energy utilisation, hypothetically could improve diabetic management and literally make a fortune for the inventor.
Resources, Risks and Regulation
It seems clear that the pharmaceutical industry does not have an independent role in innovative research in any field, but rather an interdependent one. The part it plays is extremely expensive, involving the huge costs of maintaining programmes involving chemists, physicists, experimental biologists, animal and clinical pharmacologists, pathologists, toxicologists, pharmacists, etc., together with very sophisticated and expensive equipment and back-up services. Since reliable fortune tellers are not readily available, the necessary long term investment has unpredictable returns. If a research programme succeeds in finding a likely compound active in, say, mice, it may still fall at the toxicological fence or it may lack the desired therapeutic activity in man. Unfortunately sales to mice cannot be relied on for economic survival! So innovative research is the risk component within the industry, with an estimated chance of clinical and commercial success of 1 in 10,000 chemical entities studied [13] .
Complicating innovative research are the understandable demands for more and more safety studies, which should require high scientific standards. Unfortunately the demands increase, in a quasi-scientific way, by addition rather than replacement of new tests for old, and frequently neither regulator nor regulated is sure of the relevance to man. As more and more of the research and development budget is involved in non-innovative work of this sort, less innovation is possible. Weatherall [14] discussed this in some detail. Had Banting and Best made their classical observations in the 1980's instead of the 1920's, it is likely that many years and considerable expenditure of money would have elapsed before insulin could have become widely available as a medicinal product. In the United Kingdom, in 1979, it was estimated that the average time between discovery of a new entity and marketing was 10 years at a cost of some s 20-s 30 million [2] . Cromie, in a sobering analysis, has predicted that if trends continue, by the year 2000 about 100 years of work would be needed before a company could apply for a product licence for a new entity [5] . Hopefully this is unduly pessimistic, since there are some signs of attempts to reduce the time element. In this regulatory context there is a timely and authoritative publication by Griffin and Diggle [9] , with valuable commentaries by Binns [3] and Goldberg [8] . Certainly the escalation of costs involved will further reduce the fraction of companies, worldwide, taking an active role in innovative research of any sort.
Using the United Kingdom as an example, it has been indicated that only a fraction of the pharmaceutical industry is involved in innovative research. The total industry in the United Kingdom comprises approximately 4,500 companies (Griffin JP, personal communication) holding product licences, ranging from herbalists through generic manufacturers to large research based international companies, which may have parent companies elsewhere. Products range from 'ethical' (prescription) items to 'over the counter' medicaments and tonics.
For ethical products the consumer (patient) market is defined by the medically qualified prescriber. The lay-man, perhaps aided by pharmacists or equally likely, folk-lore, can select 'over the counter' products directly. Survival of the industry in a free economy is dependent on sales and to ensure sales, promotion, advertising, making aware of products -terminology depends on the commentator -is directed at the market, which may well include one, or other, or all three of the groups mentioned. The industry has been roundly criticised for this activity and certainly examples ofunpraiseworthy activity exist. However, the distinction between the desirable and undesirable is difficult to draw and debate will continue.
The research based companies are complex, multidisciplinary scientific groups undertaking high financial risk programmes. Within a free monetary economy their products must be sold at a price sufficient to cover production and running expenses, plus something extra. That something extra has to fund the high risk researchthe 9,999 compounds that failed. In 1979, the Association of the British Pharmaceutical Industry estimated that approximately 13% of turnover in the United Kingdom pharmaceutical industry was spent on research and development [2] . With the advent of restricted formularies at World Health Organisation, national, regional and hospital level, and increasing demands for 'generics' at cost within controlled economies, it is difficult to see where the funds will come from for innovative research.
So the future is uncertain. There is no simple cure for the syndrome 'diabetes mellitus' but there are many approaches that could lead to improved management. The role of the pharmaceutical industry in supplying technical and applied research will continue, but the extent of its future role in the field of innovative research, is less clear.
